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The X-ray crystal structures of the complexes formed with bovine trypsin and the ?+‘a-tosylated pipefidides of m-amidino-, p-amidino- and p-guani- 
dino-D,L-phenylalanine (3-TAPAP, 4-TAPAP and 4-TGPAP) were determined with data to 1.8 A resolution. The L-stereoisomer of 3-TAPAP 
binds as a compact entity into the active site of trypsin, with the amiciino and the carbonyl groups of the central amidinophenylalanyl residue 
hydrogen-bonded to GIy216 of trypsin. According to modeling and energy minimization, 3-TAPAP fits perfectly in this conformation to the more 
restrictive thrombin active site also (Bajusz et al. (1978) Int. J. Pept. Prot. Res. 12, 217-221); the piperid~ne moiety extends into the cage-like S2 
subsite of thrombin, but leaves room for additional substituents which might help to improve binding and pharmacologi~l properties. in contrast, 
4-TAPAP and 4-TGPAP bind only weakly and in an extended confo~ation to trypsin; their considerably enhanced amnities for thrombin would 
suggest a more compact binding to thrombin. 
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1. INTRODUCTION 
Thrombin, a trypsin-like serine proteinase, is the 
final enzyme in both coagulation cascades and plays a 
central role in thrombosis and hemostasis. Clot forma- 
tion in various thrombotic diseases has been directly at- 
tributed to the action of thrombin. Its key role in induc- 
ing diseases like coronary thrombosis, stroke and 
pulmonary embolism points to use appropriate in- 
hibitors as therapeutic agents. A large number of 
thrombin-specific synthetic inhibitors have been found 
and tested, most of them derived from arginine, ben- 
zamidine and D-PheProArg [2-61. The experimental 
structure of human cu-thrombin in complex with D- 
PheProArgCh-2Cl [l] allows better understanding of 
the inhibitory properties and a more rational approach 
to the design of new inhibitors. 
We have recently published the X-ray structure of the 
complex formed between NAPAP (for abbreviations 
see Fig. I), the tightest binding benzamidine-based in- 
hibitor of thrombin, with bovine trypsin [7]. This ex- 
perimental structure allowed reliable modeling of the 
NAPAP-thrombin complex providing a plausible ex- 
planation for the extraordinary selectivity and high af- 
finity of NAPAP for thrombin. In the following we 
X-ray data were collected with the FAST television area detector 
(Enraf-Nonius). Evaluation (Tabfe I), modeling and refinement with 
X-PLOR [9] were done as described for NAPAP-trypsin [7]. The 
molecular models of 3.TAPAP, 4-TAPAP and 4-TGPAP (Fig. I) 
were constructed and built into electron density using MAIN [lo]. The 
structures were crystallographically refined with energy restraints us- 
ing X-PLOR version 1.5 using X-PLOR force field parameters 
(PARAMl9X.PRO) and sulphur-atom bond lengths and angles as 
c’escribcd previously [7]. The final mode and refinement parameters 
a,e given in Table 11. 
Correspondence address; D. Turk, Max-Planck-Institut fiir Bio- To model the thrombin complexes, the trypsin-bound inhibitor 
chemie, D(W)-8033 Martinsried, Germany. models were transformed to the thrombin active site [-I] and energy- 
describe the structure determinations of similar trypsin 
complexes with m-amidino-, p-amidino- and p-guani- 
dino-D,L-phenylalanine derivatives (3-TAPAP, 
4-TAPAP, 4-TGPAP: for abbreviations see Fig. l), 
and present the results of modeling with thrombin. The 
structural results are correlated with the experimeIlta1 
binding data. 
2. MATERIALS AND METHODS 
The crystallization of bovine trypsin and the crystal parameters of 
a new, more ‘open’ orthorhombic trypsin crystal form have been 
described elsewhere [7]. Large trypsin crystals were soaked for 2 to 3 
days at 20°C in a calcium-saturated 2.5 M ammonium sulphate solu- 
tion, buffered with 0.1 M phosphate to pH 8, containing about I 
mg!crrr’ of 3-TAPAP, 4.TAPAP, or 4-TGPAP (solubilired using 
small amounts of dimethyisulphoxide). 3-and J-TAPAP (Fig. I) were 
synthesized as described [S], 4.TGPAP (S-2576; Fig. 1) was purchased 
from Kabi Vitrum, Sweden. The compounds were D,L-racemates. 
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4-TAPAP 
minimired (excluding electrostatic energies) with MAIN using the 
force field parameters of X-PLOR as dewibed previously 171. 
3. RESULTS 
The topologies of the three inhibitors investigated 
together with their chemical names are given in Fig. 1. 
The 3-TAPAP molecule bound to trypsin is well defin- 
ed by electron density (Fg. 2). It is the L-stereoisomer 
which nestles into the trypsin active site in a rather cnm- 
pact conformation. Its peptide chain runs antiparallel 
to trypsin segment Ser213 - Ser”‘, forming two hy- 
drogen bonds from the amino and carbonyl group of 
Tabte I 
--. 
Parameter 3-TAPAP J-TAPAP 4-TGFAP 
Maximal reSolution 1.95 A 1.75 is I .80 A 
Number of measurements 77873 52111 61407 
K,,,,,,, Nurriber of 0.075 0.066 O.Oc)2 
independent 
reflections 18614 17191 19464 
Measured/possible reflections 
to maximal resolution 0.88 0.57 0.73 ~.I.. I._~..._ 
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the central nl-amidinophenytatanine residue to Gty”‘” 
of trypsin. 
The amidinophenyt moiety is arranged in a similar 
manner as benzamidine [ 111 and amidinophenyi pyru- 
vie acid 1121 i.e. sandwiched between trypsin segmems 
S&r”” - Ghl’“z and Trp”’ - GIy”“, which together with 
the interconnecting disulfide bridge 141-220 form the 
‘base’ and ‘ceiling’ of the trypsin specificify pocket. 
The amidino group faces the carboxylate group of 
AsplXy, and is in contact with Gly”“0 and a 
characteristic ‘buried solvent molecule at the back nf 
the pocket, thus fully exploiting its hydrogen bonding 
capacity with optimal charge compensation. 
The tosyl group, wirh slightly enhanced mobility, 
stands almost perpendicular to the indote moiety of 
Trp2’S. Both oxygen atoms of the sutphonyt group are 
well resolved in the electron density and are directed 
towards Gly”’ N and away from the trypsin surface. 
The piperidine ring, which is clearly confined to one of 
the two possible chair ~o~lforrna~jons, is piaced between 
the imidazole ring of I-Ii? and the toluene ring. ‘The 
planar amido group between the m-amidinophenylala- 
nine and the pipcridine ring is quite distant from SerlYs 
(Oy-C:5.8 A); the ‘oxyanion hole’ of trypsin is oc- 
cupied by an ordered solvent molecule (Sol”‘, Fig. 2). 
As with NAPAP-trypsin [7], the side chains of SW*‘~” 
and of His” are in an almost perfect hydrogen bonding 
arrangement (01 -NC = 2.9A). 
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Table II 
Final model and refinement parameters. The R-vatue is defined as 
ft;(/K,l;,b\/ -- jE,li) 1 z;il;;,b,i) 
Parameter 3-TAPAP 4-TAPAP 4-TGPAP 
Number of non-hydrogen protein atoms 1629 1629 1629 
Number of non-hydrogen inhibitor atoms 30 30 31 
Number of solvent molecules 214 147 243 
Calcium ion I 1 I 
sof- t 
Overall R-value II.7 A2 12.5 A’ 13.8 A’ 
Rms standard deviation from target values 
Bond lengths 
Bond angles 
Number of unique reflections used 
for refinement 
Resolution range 
H-VdUC 
3 2. Crystal structwes of trypsin-4- TGPA P and 
trypsin-4- TAPA P 
The active site of the trypsin-4-TGPAP complex is 
shown in Fig. 3 together with the electron density 
calculated with phases obtained with the refined model. 
In contrast to the trypsin complex formed with 3- 
TAPAP, the density representing 4-TGPAP is weaker 
and less structured, so that no unequivocal inhibitor 
model interpretation is possible. The 4-TGPAP model 
shown in Fig. 3 represents the best fit to the density 
obtained from crystallographic refinement. 
(i) The density within the specificity pocket (Fig. 3) can 
account for the guan~di~o phenylalanyl side chain; Fig. 
- 
0.011 A 0.0t2 A O.OlZ A 
2.33” 2.57” 2.67” 
is199 I4781 18091 
8.0-1.90 A 8.0-l .90 a 8.0-l .90 A 
0.167 0.178 0.169 
__- 
3 shows just one of two alternative orientations of the 
guanidyl group. 
(ii) The density around its a-carbon seems onIy to be in 
agreement with the ~-s~~reo~onfiguration. 
(iii) Appropriate density exists to localize the sulphonyf 
moiety (with one of both S-U groups in hydrogen bond 
distance from Cly”‘6N). 
(iv) There is, however, no significant density which 
could account for the toluene group even at low con- 
touring levels. A similar situation of an undefined, i.e. 
mobile toluene group has been found for N-tosyl-lysyl- 
chloromethyl-ketone-trypsin [ 131. 
(v) The density extending along Ser’“’ (opposite to the 
sulphonyl group, Fig. 3) has been assigned to the car- 
bonyi group and the adjacent piperidine ring. However 
Fig. 2. Active&c region of the complex formed between II-TAPAP (thick connections) and bovine trypsin (thin connections) superimposed with 
the final 2F,,b, -FLalL etectran density. The view is towards the trypsin surface: the active-site residues are to the right, the specificity pocket is at 
the back. Crosses indicate focalized solvent moiecufes. The density is calculated with phases omitting the inhibitor atoms, contoured at 1.0~. 
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Fig. 3. Active-site region of the complex formed bet\veen 4.TGPAP (thick conections) and hoLine tr-yprin (thin connections) as in Fig. 2 
its placement along the His” imidazole ring (i.e. in the 
vertical density stretch in Fig. 3) is also possible. 
The density for crystals containing 1 mM D,L-4- 
TAPAP was even more broken and difficult to inter- 
pret. The trypsin binding site should be completely 
saturated at this concentration, if the dissociation con- 
stant (Table III) is not affected by the crystal (salt and 
contact) conditions. The weak density presumably in- 
dicates that 4-TAPAP does not bind with one preferred 
arrangement to the active site of trypsin. 
3.3. Models of throwbin compleses 
The active-site region of the human cu-thrombin 
structure [l] overlaid with the transformed model of 
3-TAPAP (after energy minimization) is shown in Fig. 
4 together with the thrombin Connolly surface. The 
3-TAPAP molecule fits almost perfectly in its trypsin 
binding conformation (Fig. 2) to the more restrictive 
thrombin active site. The amidinophenyl moiety of 
3-TAPAP is similarly placed in the thrombin specificity 
pocket as that of NAPAP [7]; the arrangement of the 
‘main chain’ atoms of 3-TAPAP (with a phenylalaline 
Table III 
Inhibition constants (K,l/lmol/l]) of bovine trypcin, human and 
bo\ ine thrombin 
Inhibitor 
3.TAPAP 
4.TAPAP 
4.TGPAP 
MQPA 
NAPAP 
Human 
thrombin 
0.54 
0.64 
0.45 
0.019 
0.0066 
Bo\ ine 
thrombin 
0.34 
1.3 
0.57 
0.006 
Boclne 
trypin 
I .z 
64.0 
100.0 
5.0 
0.69 
L-stereoisomer) and the two hydrogen bonds formed 
with G~Y”‘~ are, however, relatively similar to that 
found for MQPA [7,14]. The toluene group of 3- 
TAPAP can be arranged as in the trypsin structure. In 
thrombin, however, it finds a much more notched and 
hydrophobic cleft (the ‘aryl binding site’, made up by 
Ile”‘, Trp” and Leu”‘) (Fig. 4). The piperidine group 
of 3-TAPAP extends into the thrombin S2-cavity, but 
does not fill it up tightly. 
For the corresponding modelling of the thrombin 
complexes with 4-TGPAP and 4-TAPAP several alter- 
native conformations are conceivable. The ‘external’ 
positioning of their piperidine rings (as shown in Fig. 3 
for the trypsin complex) seems in thrombin less prob- 
able. Their considerably stronger binding to thrombin 
compared with trypsin suggests that both p-substituted 
inhibitors interact more tightly with the furrowed 
active-side surface of thrombin. 
4. DISCUSSION 
The crystal structures of the trypsin complexes and 
the model structures of the thrombin complexes 
presented in this and in the preceding paper [7] reveal 
some more general rules for the arrangement of the 
amidino- and guanidino phenylalanine derivatives. In 
these complexes two interactions are observed (for 
both, trypsin as well as thrombin). 
(i) The amidino or the guanidino group is placed adja- 
cent to carboxylate group of Asp”” allowing a 
favourable hydrogen bond/salt bridge interaction. 
(ii) The inhibitor is connected through at least one, but 
optimally two hydrogen bonds to both projecting polar 
groups of G~Y”~. In the case of NAPAP [7] the glycine 
136 
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Fig. 4. Active-site regiot~ of thrombin including Connolly surface with proposed models of MQPA (thin line inhibltorL NAPAP (thicker line in- 
hibitor) and 3~TAPAP (the thickest line inhibitor). 
'spacer' forms these two hydrogen bonds with Gly ~6 
(Fig. 4), while in the case of 3-TAPAP and MQPA (and 
probably also 3-TGAP - for explanation see legend to 
Fig. 5) [7,t4] the amido and the carbonyl group of the 
central phenylalanine residue mediate this interaction 
(Fig, 5). 
The formation of one (to Gty2t6N) or two hydrogen 
bonds and the simultaneous favourable insertion of the 
phenylalanine moiety into the specificity pocket require 
an L-configuration of the central phenytatanyI residue 
in the '3-TAPAP-like' arrangement, but a D-configura- 
tion in the 'NAPAP~Iike' arrangement (Fig. 4), Model 
building studies suggest that binding of the correspond-- 
ing enantiomeric forms in either position would b ex- 
tremely unfavourable, 
These interactions at the central inhibitor residue(s) 
are equally possible in trypsin and in thrombin. Throm- 
bin, however, offers different (additional) docking sites 
Fig. 5. Active-site region of thrombin including Connolly surface with proposed models of MQPA (thin line inhibitor), 3-TAPAP (thicker line 
inhibitor) and 3-TGPAP (the thickest llne inhibitor). The geometry of 3-TGPAP model is based on te assumption that the binding configuration 
at C~ is L. The C~,' chirality was postulated as L, since it is possible to achieve a similar distanc between the central carbon atom of the guanidiuo 
group to the Cce as in MQPA a~d 3-TAPAP. The 3-TGPAP guanidino group is supposed to bind in an orientation similar to MQPA, with only 
one nitrogen atom pointing towards the Asp *'~9 (the 3-TGPAP has, as far as we.know, not been synthesized yet). 
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for interaction with the peripheral inhibitor groups, 
namely (i) a much more notched hydrophobic ‘aryl- 
binding site’ [7], and (ii) a cavity-like S2-subsite. 
NAPAP takes advantage of both thrombin sites 
through interaction with its naphtyl and unsubstituted 
piperidine moieties (see Fig. 4); these additional favour- 
able interactions account for the enhanced thrombin 
binding compared with trypsin [7] (Table III). 
The toluene group of 3-TAPAP can likewise interact 
favourably with the aryl-binding site of thrombin; its 
piperidine ring fills the S2-subsite only loosely; pre- 
sumably, this improper fit results in an only moderately 
increased affinity to thrombin compared with trypsin 
(Table III). There would be some empty space for addi- 
tional substitution of a small hydrophobic group in the 
equatorial 4-position (Fig. 4), which could render a 
3-TAPAP derivative a tighter binding thrombin in- 
hibitor; a likewise favourable substitution has been 
found for MQPA [2] (see Fig. 4). 3-TAPAP seems to be 
a particularly attractive starting molecule for derivati- 
zations, as the position of its piperidine in thrombin 
allows a further substitution in the 2-position (with D- 
configuration) by alkyl chains, which in turn could be 
equipped with polar groups to allow further favourable 
interactions with the oxyanion hole and with the 
Sl ‘-subsite of thrombin. 
Binding in the ‘3-TAPAP-like’ position (with L- 
configuration) is for the p-substituted phenylalanine 
derivatives (4-TAPAP and 4-TGPAP) unlikely due to 
primarily unfavourable amidino/guanidino group 
orientations with respect to Asp”“, but also to the large 
distances between the carbon atom of the charged 
group (amidino, guanidino) and the Ccu of the phenyl- 
alanyi moieties (6.2 i\ in 4-TAPAP and NAPAP, above 
7.0 A in 4-TGPAP, compared with 5.7 A in 3-TAPAP). 
4-TAPAP and 4-TGPAP in a ‘NAPAP-like’ position 
(with D-configuration) could only form one hydrogen 
bond (between the sulphonyl and Gly”“N, see Fig. 4); 
their weak interaction with the trypsin active site pro- 
bably gives rise to the weak density (Fig. 3) and to the 
low affinities for trypsin (Table III). The additional 
tight interactions of the toluene and the piperidine 
moieties and perhaps another binding mode with 
thrombin would probably result in a stronger fixation 
and in higher affinities (Table III). This suggests that 
the binding of 4-TAPAP and 4-TGPAP tolvards 
thrombin is not equivalent to the binding to trypsin (in 
contrast to the arrangement of 3-TAPAP, NAPAP and 
MQPA). Certainty can probably only be achieved by 
determining crystalline thrombin complexes; cor- 
responding experiments are in progress. 
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